{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:40:32Z","timestamp":1782783632688,"version":"3.54.5"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-10730-y","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T10:47:13Z","timestamp":1745837233000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative evaluation of five \u03b2-Lactamase inhibitors in combination with \u03b2-Lactams against multidrug-resistant Mycobacterium tuberculosis in vitro"],"prefix":"10.1186","volume":"25","author":[{"given":"Jie","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danwei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyue","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yankun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingyong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"issue":"23","key":"10730_CR1","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMoa1108789","volume":"366","author":"Y Zhao","year":"2012","unstructured":"Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012;366(23):2161\u201370. https:\/\/doi.org\/10.1056\/NEJMoa1108789.","journal-title":"N Engl J Med"},{"key":"10730_CR2","doi-asserted-by":"publisher","unstructured":"Mustazzolu A, Borroni E, Cirillo DM, et al. Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009\u20132016. Eur Respir J. 2018;52(1). https:\/\/doi.org\/10.1183\/13993003.00070-2018.","DOI":"10.1183\/13993003.00070-2018"},{"key":"10730_CR3","unstructured":"World Health Organization. and Global Tuberculosis Programme., Global tuberculosis control: WHO report. 2021, Global Tuberculosis Programme: Geneva. p. 15 volumes."},{"issue":"3","key":"10730_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1473-3099(09)70041-6","volume":"9","author":"EW Orenstein","year":"2009","unstructured":"Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9(3):153\u201361. https:\/\/doi.org\/10.1016\/S1473-3099(09)70041-6.","journal-title":"Lancet Infect Dis"},{"key":"10730_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1146\/annurev-med-040717-051502","volume":"70","author":"KV Dicks","year":"2019","unstructured":"Dicks KV, Stout JE. Molecular diagnostics for Mycobacterium tuberculosis infection. Annu Rev Med. 2019;70:77\u201390. https:\/\/doi.org\/10.1146\/annurev-med-040717-051502.","journal-title":"Annu Rev Med"},{"issue":"7331","key":"10730_CR6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nature09657","volume":"469","author":"A Koul","year":"2011","unstructured":"Koul A, Arnoult E, Lounis N, et al. The challenge of new drug discovery for tuberculosis. Nature. 2011;469(7331):483\u201390. https:\/\/doi.org\/10.1038\/nature09657.","journal-title":"Nature"},{"issue":"7","key":"10730_CR7","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1016\/S1473-3099(18)30111-7","volume":"18","author":"G Walzl","year":"2018","unstructured":"Walzl G, McNerney R, Plessis Ndu, et al. Tuberculosis: advances and challenges in development of new diagnostics and biomarkers. Lancet Infect Dis. 2018;18(7):e199\u2013210. https:\/\/doi.org\/10.1016\/S1473-3099(18)30111-7.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10730_CR8","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.cell.2020.01.021","volume":"180","author":"JM Stokes","year":"2020","unstructured":"Stokes JM, Yang K, Swanson K, et al. A deep learning approach to antibiotic discovery. Cell. 2020;180(4):688\u2013702. https:\/\/doi.org\/10.1016\/j.cell.2020.01.021. e13.DOI:.","journal-title":"Cell"},{"key":"10730_CR9","doi-asserted-by":"publisher","unstructured":"Yahav D, Giske CG, Gramatniece A, et al. New beta-Lactam-beta-Lactamase inhibitor combinations. Clin Microbiol Rev. 2020;34(1). https:\/\/doi.org\/10.1128\/CMR.00115-20.","DOI":"10.1128\/CMR.00115-20"},{"issue":"2","key":"10730_CR10","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1093\/jac\/dks395","volume":"68","author":"X Gonzalo","year":"2013","unstructured":"Gonzalo X, Drobniewski F. Is there a place for beta-lactams in the treatment of multidrug-resistant\/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin\/clavulanate. J Antimicrob Chemother. 2013;68(2):366\u20139. https:\/\/doi.org\/10.1093\/jac\/dks395.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10730_CR11","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1586\/eri.12.96","volume":"10","author":"SG Kurz","year":"2012","unstructured":"Kurz SG, Bonomo RA. Reappraising the use of beta-lactams to treat tuberculosis. Expert Rev Anti Infect Ther. 2012;10(9):999\u20131006. https:\/\/doi.org\/10.1586\/eri.12.96.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"9","key":"10730_CR12","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/ja.2014.94","volume":"67","author":"CN Wivagg","year":"2014","unstructured":"Wivagg CN, Bhattacharyya RP, Hung DT. Mechanisms of beta-lactam killing and resistance in the context of Mycobacterium tuberculosis. J Antibiot (Tokyo). 2014;67(9):645\u201354. https:\/\/doi.org\/10.1038\/ja.2014.94.","journal-title":"J Antibiot (Tokyo)"},{"issue":"12","key":"10730_CR13","doi-asserted-by":"publisher","first-page":"6085","DOI":"10.1128\/AAC.01253-13","volume":"57","author":"SG Kurz","year":"2013","unstructured":"Kurz SG, Wolff KA, Hazra S, et al. Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis beta-Lactamase BlaC lead to clavulanate resistance? A biochemical rationale for the use of beta-lactam-beta-lactamase inhibitor combinations. Antimicrob Agents Chemother. 2013;57(12):6085\u201396. https:\/\/doi.org\/10.1128\/AAC.01253-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10730_CR14","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/infdis\/jis460","volume":"207","author":"KE Dooley","year":"2013","unstructured":"Dooley KE, Obuku EA, Durakovic N, et al. World health organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis. 2013;207(9):1352\u20138. https:\/\/doi.org\/10.1093\/infdis\/jis460.","journal-title":"J Infect Dis"},{"key":"10730_CR15","doi-asserted-by":"publisher","unstructured":"Tiberi S, Payen MC, Sotgiu G et al. Effectiveness and safety of meropenem\/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. Eur Respir J, 2016. 47(4): pp. 1235\u201343.https:\/\/doi.org\/10.1183\/13993003.02146-2015","DOI":"10.1183\/13993003.02146-2015"},{"issue":"4","key":"10730_CR16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1164\/rccm.v201erratum2","volume":"201","author":"Erratum","year":"2020","unstructured":"Erratum. Treatment of Drug-Resistant tuberculosis. An official ATS\/CDC\/ERS\/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2020;201(4):500\u20131. https:\/\/doi.org\/10.1164\/rccm.v201erratum2.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10730_CR17","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.1128\/AAC.00171-15","volume":"59","author":"L Davies Forsman","year":"2015","unstructured":"Davies Forsman L, Giske CG, Bruchfeld J, et al. Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015;59(6):3630\u20132. https:\/\/doi.org\/10.1128\/AAC.00171-15.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10730_CR18","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1128\/AAC.49.7.2816-2821.2005","volume":"49","author":"HF Chambers","year":"2005","unstructured":"Chambers HF, Turner J, Schecter GF, et al. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother. 2005;49(7):2816\u201321. https:\/\/doi.org\/10.1128\/AAC.49.7.2816-2821.2005.","journal-title":"Antimicrob Agents Chemother"},{"key":"10730_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.addr.2016.04.026","volume":"102","author":"DT Hoagland","year":"2016","unstructured":"Hoagland DT, Liu J, Lee RB, et al. New agents for the treatment of drug-resistant Mycobacterium tuberculosis. Adv Drug Deliv Rev. 2016;102:55\u201372. https:\/\/doi.org\/10.1016\/j.addr.2016.04.026.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5918","key":"10730_CR20","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1126\/science.1167498","volume":"323","author":"JE Hugonnet","year":"2009","unstructured":"Hugonnet JE, Tremblay LW, Boshoff HI, et al. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science. 2009;323(5918):1215\u20138. https:\/\/doi.org\/10.1126\/science.1167498.","journal-title":"Science"},{"issue":"4","key":"10730_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5365\/wpsar.2022.13.4.972","volume":"13","author":"KH Oh","year":"2022","unstructured":"Oh KH, Quelapio MI, Morishita F, et al. Progress on diagnosis and treatment of drug-resistant tuberculosis in line with world health organization recommendations in six priority countries in the Western Pacific region. Western Pac Surveill Response J. 2022;13(4):1\u201312. https:\/\/doi.org\/10.5365\/wpsar.2022.13.4.972.","journal-title":"Western Pac Surveill Response J"},{"issue":"4","key":"10730_CR22","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.ccm.2019.08.002","volume":"40","author":"SR Mase","year":"2019","unstructured":"Mase SR, Chorba T. Treatment of Drug-Resistant tuberculosis. Clin Chest Med. 2019;40(4):775\u201395. https:\/\/doi.org\/10.1016\/j.ccm.2019.08.002.","journal-title":"Clin Chest Med"},{"key":"10730_CR23","doi-asserted-by":"publisher","unstructured":"Mirzayev F, Viney K, Linh NN, et al. World health organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. Eur Respir J. 2021;57(6). https:\/\/doi.org\/10.1183\/13993003.03300-2020.","DOI":"10.1183\/13993003.03300-2020"},{"issue":"22","key":"10730_CR24","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1021\/bi500339j","volume":"53","author":"S Hazra","year":"2014","unstructured":"Hazra S, Xu H, Blanchard JS. Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the beta-lactamase from Mycobacterium tuberculosis. Biochemistry. 2014;53(22):3671\u20138. https:\/\/doi.org\/10.1021\/bi500339j.","journal-title":"Biochemistry"},{"issue":"11","key":"10730_CR25","doi-asserted-by":"publisher","first-page":"7010","DOI":"10.1128\/AAC.03539-14","volume":"58","author":"Y Horita","year":"2014","unstructured":"Horita Y, Maeda S, Kazumi Y, et al. In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with beta-lactamase inhibitors. Antimicrob Agents Chemother. 2014;58(11):7010\u20134. https:\/\/doi.org\/10.1128\/AAC.03539-14.","journal-title":"Antimicrob Agents Chemother"},{"issue":"29","key":"10730_CR26","doi-asserted-by":"publisher","first-page":"11663","DOI":"10.1073\/pnas.1205073109","volume":"109","author":"DE Ehmann","year":"2012","unstructured":"Ehmann DE, Jahic H, Ross PL, et al. Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor. Proc Natl Acad Sci U S A. 2012;109(29):11663\u20138. https:\/\/doi.org\/10.1073\/pnas.1205073109.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10730_CR27","doi-asserted-by":"publisher","unstructured":"Kaushik A, Ammerman NC, Lee J, et al. Vitro activity of the new beta-Lactamase inhibitors relebactam and vaborbactam in combination with beta-Lactams against Mycobacterium abscessus complex clinical isolates. Antimicrob Agents Chemother. 2019;63(3). https:\/\/doi.org\/10.1128\/AAC.02623-18.","DOI":"10.1128\/AAC.02623-18"},{"key":"10730_CR28","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.2147\/IDR.S260161","volume":"13","author":"J Shi","year":"2020","unstructured":"Shi J, Su R, Zheng D, et al. Pyrazinamide resistance and mutation patterns among Multidrug-Resistant Mycobacterium tuberculosis from Henan Province. Infect Drug Resist. 2020;13:2929\u201341. https:\/\/doi.org\/10.2147\/IDR.S260161.","journal-title":"Infect Drug Resist"},{"issue":"5","key":"10730_CR29","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.ijantimicag.2019.06.002","volume":"54","author":"G Li","year":"2019","unstructured":"Li G, Xu Z, Jiang Y, et al. Synergistic activities of Clofazimine with Moxifloxacin or capreomycin against Mycobacterium tuberculosis in China. Int J Antimicrob Agents. 2019;54(5):642\u20136. https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.06.002.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10730_CR30","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/s12879-018-3351-y","volume":"18","author":"J Shi","year":"2018","unstructured":"Shi J, Zheng D, Zhu Y, et al. Role of MIRU-VNTR and spoligotyping in assessing the genetic diversity of Mycobacterium tuberculosis in Henan Province, China. BMC Infect Dis. 2018;18(1):447. https:\/\/doi.org\/10.1186\/s12879-018-3351-y.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10730_CR31","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1128\/jcm.31.6.1435-1438.1993","volume":"31","author":"T Kocagoz","year":"1993","unstructured":"Kocagoz T, Yilmaz E, Ozkara S, et al. Detection of Mycobacterium tuberculosis in sputum samples by polymerase chain reaction using a simplified procedure. J Clin Microbiol. 1993;31(6):1435\u20138. https:\/\/doi.org\/10.1128\/jcm.31.6.1435-1438.1993.","journal-title":"J Clin Microbiol"},{"key":"10730_CR32","doi-asserted-by":"publisher","unstructured":"Li F, Wan L, Xiao T et al. In Vitro Activity of beta-Lactams in Combination with beta-Lactamase Inhibitors against Mycobacterium tuberculosis Clinical Isolates. Biomed Res Int, 2018. 2018: p. 3579832.https:\/\/doi.org\/10.1155\/2018\/3579832","DOI":"10.1155\/2018\/3579832"},{"key":"10730_CR33","doi-asserted-by":"publisher","unstructured":"Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev, 2005. 18(4): pp. 657\u2013\u200986.https:\/\/doi.org\/10.1128\/CMR.18.4.657-686.2005","DOI":"10.1128\/CMR.18.4.657-686.2005"},{"issue":"4","key":"10730_CR34","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1128\/AAC.04164-14","volume":"59","author":"DR Nair","year":"2015","unstructured":"Nair DR, Monteiro JM, Memmi G, et al. Characterization of a novel small molecule that potentiates beta-lactam activity against gram-positive and gram-negative pathogens. Antimicrob Agents Chemother. 2015;59(4):1876\u201385. https:\/\/doi.org\/10.1128\/AAC.04164-14.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10730_CR35","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/jam.14478","volume":"128","author":"R Singh","year":"2020","unstructured":"Singh R, Dwivedi SP, Gaharwar US, et al. Recent updates on drug resistance in Mycobacterium tuberculosis. J Appl Microbiol. 2020;128(6):1547\u201367. https:\/\/doi.org\/10.1111\/jam.14478.","journal-title":"J Appl Microbiol"},{"issue":"18","key":"10730_CR36","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1016\/j.jmb.2019.04.002","volume":"431","author":"CL Tooke","year":"2019","unstructured":"Tooke CL, Hinchliffe P, Bragginton EC, et al. beta-Lactamases and beta-Lactamase inhibitors in the 21st century. J Mol Biol. 2019;431(18):3472\u2013500. https:\/\/doi.org\/10.1016\/j.jmb.2019.04.002.","journal-title":"J Mol Biol"},{"issue":"5","key":"10730_CR37","doi-asserted-by":"publisher","first-page":"9654","DOI":"10.3390\/ijms16059654","volume":"16","author":"JH Jeon","year":"2015","unstructured":"Jeon JH, Lee JH, Lee JJ, et al. Structural basis for carbapenem-hydrolyzing mechanisms of carbapenemases conferring antibiotic resistance. Int J Mol Sci. 2015;16(5):9654\u201392. https:\/\/doi.org\/10.3390\/ijms16059654.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10730_CR38","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00894-021-04760-x","volume":"27","author":"L Sun","year":"2021","unstructured":"Sun L, Fan H, Zhong S. Evaluating the covalent binding of carbapenems on BlaC using noncovalent interactions. J Mol Model. 2021;27(6):161. https:\/\/doi.org\/10.1007\/s00894-021-04760-x.","journal-title":"J Mol Model"},{"key":"10730_CR39","doi-asserted-by":"publisher","unstructured":"Zandi TA, Townsend CA. Competing off-loading mechanisms of meropenem from an l,d-transpeptidase reduce antibiotic effectiveness. Proc Natl Acad Sci U S A. 2021;118(27). https:\/\/doi.org\/10.1073\/pnas.2008610118.","DOI":"10.1073\/pnas.2008610118"},{"issue":"12","key":"10730_CR40","doi-asserted-by":"publisher","first-page":"5940","DOI":"10.1128\/AAC.01663-13","volume":"57","author":"M Cordillot","year":"2013","unstructured":"Cordillot M, Dubee V, Triboulet S, et al. In vitro cross-linking of Mycobacterium tuberculosis peptidoglycan by L,D-transpeptidases and inactivation of these enzymes by carbapenems. Antimicrob Agents Chemother. 2013;57(12):5940\u20135. https:\/\/doi.org\/10.1128\/AAC.01663-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10730_CR41","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/jac\/dkt410","volume":"69","author":"D Soroka","year":"2014","unstructured":"Soroka D, Dubee V, Soulier-Escrihuela O, et al. Characterization of broad-spectrum Mycobacterium abscessus class A beta-lactamase. J Antimicrob Chemother. 2014;69(3):691\u20136. https:\/\/doi.org\/10.1093\/jac\/dkt410.","journal-title":"J Antimicrob Chemother"},{"key":"10730_CR42","doi-asserted-by":"publisher","unstructured":"Story-Roller E, Maggioncalda EC, Lamichhane G. Synergistic efficacy of beta-Lactam combinations against Mycobacterium abscessus pulmonary infection in mice. Antimicrob Agents Chemother. 2019;63(8). https:\/\/doi.org\/10.1128\/AAC.00614-19.","DOI":"10.1128\/AAC.00614-19"},{"issue":"1","key":"10730_CR43","doi-asserted-by":"publisher","first-page":"e0003922","DOI":"10.1128\/msphere.00039-22","volume":"7","author":"G Kumar","year":"2022","unstructured":"Kumar G, Galanis C, Batchelder HR, et al. Penicillin binding proteins and beta-Lactamases of Mycobacterium tuberculosis: reexamination of the historical paradigm. mSphere. 2022;7(1):e0003922. https:\/\/doi.org\/10.1128\/msphere.00039-22.","journal-title":"mSphere"},{"issue":"6","key":"10730_CR44","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1128\/AAC.00023-13","volume":"57","author":"S Solapure","year":"2013","unstructured":"Solapure S, Dinesh N, Shandil R, et al. In vitro and in vivo efficacy of beta-lactams against replicating and slowly growing\/nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2013;57(6):2506\u201310. https:\/\/doi.org\/10.1128\/AAC.00023-13.","journal-title":"Antimicrob Agents Chemother"},{"key":"10730_CR45","doi-asserted-by":"publisher","unstructured":"Fisher JF, Mobashery S. beta-Lactam resistance mechanisms: Gram-Positive Bacteria and Mycobacterium tuberculosis. Cold Spring Harb Perspect Med. 2016;6(5). https:\/\/doi.org\/10.1101\/cshperspect.a025221.","DOI":"10.1101\/cshperspect.a025221"},{"issue":"8","key":"10730_CR46","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1021\/acsinfecdis.1c00185","volume":"7","author":"R Gupta","year":"2021","unstructured":"Gupta R, Al-Kharji N, Alqurafi MA, et al. Atypically modified carbapenem antibiotics display improved antimycobacterial activity in the absence of beta-Lactamase inhibitors. ACS Infect Dis. 2021;7(8):2425\u201336. https:\/\/doi.org\/10.1021\/acsinfecdis.1c00185.","journal-title":"ACS Infect Dis"},{"issue":"Suppl 1","key":"10730_CR47","doi-asserted-by":"publisher","first-page":"pi3","DOI":"10.1093\/jac\/dkh050","volume":"53","author":"AR White","year":"2004","unstructured":"White AR, Kaye C, Poupard J, et al. Augmentin (amoxicillin\/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother. 2004;53(Suppl 1):pi3\u201320. https:\/\/doi.org\/10.1093\/jac\/dkh050.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"10730_CR48","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.7150\/thno.56205","volume":"11","author":"Y Liu","year":"2021","unstructured":"Liu Y, Tong Z, Shi J, et al. Drug repurposing for next-generation combination therapies against multidrug-resistant bacteria. Theranostics. 2021;11(10):4910\u201328. https:\/\/doi.org\/10.7150\/thno.56205.","journal-title":"Theranostics"},{"issue":"3","key":"10730_CR49","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4103\/ijmy.ijmy_131_23","volume":"12","author":"V Andersson","year":"2023","unstructured":"Andersson V, Froberg G, Dahl VN, et al. The in vitro activity of carbapenems alone and in combination with beta-lactamase inhibitors against difficult-to-treat mycobacteria; Mycobacterium tuberculosis, Mycobacterium abscessus, and Mycobacterium avium complex: A systematic review. Int J Mycobacteriol. 2023;12(3):211\u201325. https:\/\/doi.org\/10.4103\/ijmy.ijmy_131_23.","journal-title":"Int J Mycobacteriol"},{"issue":"17","key":"10730_CR50","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1021\/bi100232q","volume":"49","author":"LW Tremblay","year":"2010","unstructured":"Tremblay LW, Fan F, Blanchard JS. Biochemical and structural characterization of Mycobacterium tuberculosis beta-lactamase with the carbapenems ertapenem and doripenem. Biochemistry. 2010;49(17):3766\u201373. https:\/\/doi.org\/10.1021\/bi100232q.","journal-title":"Biochemistry"},{"issue":"6","key":"10730_CR51","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1093\/jac\/dkx022","volume":"72","author":"JS Cavanaugh","year":"2017","unstructured":"Cavanaugh JS, Jou R, Wu MH, et al. Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported Pharmacokinetic\/pharmacodynamic parameters. J Antimicrob Chemother. 2017;72(6):1678\u201387. https:\/\/doi.org\/10.1093\/jac\/dkx022.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10730_CR52","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/phar.2614","volume":"41","author":"V Sodhi","year":"2021","unstructured":"Sodhi V, Kronsberg KA, Clark M, et al. Tebipenem pivoxil hydrobromide-No PICC, no problem! Pharmacotherapy. 2021;41(9):748\u201361. https:\/\/doi.org\/10.1002\/phar.2614.","journal-title":"Pharmacotherapy"},{"issue":"8","key":"10730_CR53","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1128\/AAC.00665-12","volume":"56","author":"V Dubee","year":"2012","unstructured":"Dubee V, Triboulet S, Mainardi JL, et al. Inactivation of Mycobacterium tuberculosis l,d-transpeptidase LdtMt(1) by carbapenems and cephalosporins. Antimicrob Agents Chemother. 2012;56(8):4189\u201395. https:\/\/doi.org\/10.1128\/AAC.00665-12.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10730_CR54","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1208\/s12248-018-0193-x","volume":"20","author":"K Gokulan","year":"2018","unstructured":"Gokulan K, Khare S, Cerniglia CE, et al. Structure and inhibitor specificity of L,D-Transpeptidase (LdtMt2) from Mycobacterium tuberculosis and antibiotic resistance: calcium binding promotes dimer formation. AAPS J. 2018;20(2):44. https:\/\/doi.org\/10.1208\/s12248-018-0193-x.","journal-title":"AAPS J"},{"key":"10730_CR55","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/CE.S40698","volume":"9","author":"P Lagace-Wiens","year":"2014","unstructured":"Lagace-Wiens P, Walkty A, Karlowsky JA. Ceftazidime-avibactam: an evidence-based review of its Pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid. 2014;9:13\u201325. https:\/\/doi.org\/10.2147\/CE.S40698.","journal-title":"Core Evid"},{"issue":"22","key":"10730_CR56","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1021\/bi300508r","volume":"51","author":"H Xu","year":"2012","unstructured":"Xu H, Hazra S, Blanchard JS. NXL104 irreversibly inhibits the beta-lactamase from Mycobacterium tuberculosis. Biochemistry. 2012;51(22):4551\u20137. https:\/\/doi.org\/10.1021\/bi300508r.","journal-title":"Biochemistry"},{"issue":"39","key":"10730_CR57","doi-asserted-by":"publisher","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","volume":"288","author":"DE Ehmann","year":"2013","unstructured":"Ehmann DE, Jahic H, Ross PL, et al. Kinetics of avibactam Inhibition against class A, C, and D beta-lactamases. J Biol Chem. 2013;288(39):27960\u201371. https:\/\/doi.org\/10.1074\/jbc.M113.485979.","journal-title":"J Biol Chem"},{"issue":"5","key":"10730_CR58","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1128\/jcm.34.5.1321-1322.1996","volume":"34","author":"TD Moore","year":"1996","unstructured":"Moore TD, Horton R, Utrup LJ, et al. Stability of amoxicillin-clavulanate in BACTEC medium determined by high-performance liquid chromatography and bioassay. J Clin Microbiol. 1996;34(5):1321\u20132. https:\/\/doi.org\/10.1128\/jcm.34.5.1321-1322.1996.","journal-title":"J Clin Microbiol"},{"key":"10730_CR59","doi-asserted-by":"publisher","unstructured":"Farmer TH, Degnan BA, Payne DJ. Penetration of beta-lactamase inhibitors into the periplasm of gram-negative bacteria. FEMS Microbiol Lett, 1999. 176(1): pp. 11\u2013\u20095.https:\/\/doi.org\/10.1111\/j.1574-6968.1999.tb13635.x","DOI":"10.1111\/j.1574-6968.1999.tb13635.x"},{"issue":"28","key":"10730_CR60","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1021\/acs.biochem.1c00168","volume":"60","author":"I van Alen","year":"2021","unstructured":"van Alen I, Chikunova A, Safeer AA, et al. The G132S mutation enhances the resistance of Mycobacterium tuberculosis beta-Lactamase against sulbactam. Biochemistry. 2021;60(28):2236\u201345. https:\/\/doi.org\/10.1021\/acs.biochem.1c00168.","journal-title":"Biochemistry"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10730-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-10730-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10730-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T10:47:17Z","timestamp":1745837237000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-10730-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10730"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-10730-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"10 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and approved by the Medical Ethics Committee of the Henan Provincial Center for Disease Control and Prevention(Number: 2023-KY-002-02).Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"619"}}